ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
COVID-19 Associated Coagulopathy and Thrombotic Complications.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Pulmonary Embolism in COVID-19: Trends from a Single-Center Study Across Ten Pandemic Waves in Romania.Microorganisms · 2025Article
- Roles of spectral dual-layer CT, D-dimer concentration, and COVID-19 pneumonia in diagnosis of pulmonary embolism.European journal of radiology open · 2024Article
- Spectrum of Thrombotic Complications in Fatal Cases of COVID-19: Focus on Pulmonary Artery Thrombosis In Situ.Viruses · 2023Article
- Comorbidities and clinical complications associated with SARS-CoV-2 infection: an overview.Clinical and experimental medicine · 2023Review
- Deep vein thrombosis of lower limbs in patients with COVID-19.Jornal vascular brasileiro · 2023Review
- Coagulation Profile of COVID-19 Patients.Life (Basel, Switzerland) · 2022Review
- Early-stage COVID-19 pandemic observations on pulmonary embolism using nationwide multi-institutional data harvesting.NPJ digital medicine · 2022Article
- Spontaneous hyphema in the setting of COVID-19 pneumonia.American journal of ophthalmology case reports · 2022Article
- Pathological effects of SARS-CoV-2 on hematological and immunological cells: Alterations in count, morphology, and function.Pathology, research and practice · 2022Review
- Two Different Clinical Presentations of Acute Limb Ischemia Caused by Acute Thrombotic Events in COVID-19.Cureus · 2021Article
- Case of right ventricular and aortic thrombi in a patient with severe COVID-19.BMJ case reports · 2021Article
- Extensive Arterial Thrombus Following Discharge after a Covid-19 Infection.Annals of vascular surgery · 2021Article
- Systemic arterio-venous thrombosis in COVID-19: A pictorial review.World journal of radiology · 2021Review
- Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CLEuropean journal of pharmacology · 2021Review
- A case report of multisite arterial thrombosis in a patient with coronavirus disease 2019 (COVID-19).European heart journal. Case reports · 2021Article
- More Severe Hypercoagulable State in Acute COVID-19 Pneumonia as Compared With Other Pneumonia.Mayo Clinic proceedings. Innovations, quality & outcomes · 2020Article
- Is Thrombophilic Genetic Profile Responsible for an Acute Ischemic Stroke in a COVID-19 Male Patient?Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
- Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries.Cardiovascular pathology : the official journal of the Society for Cardiovascular PathologyReview
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SARS-CoV-2 virus caused a global pandemic within weeks, causing hundreds of thousands of people infected. Many patients with severe COVID-19 present with coagulation abnormalities, including increase D-dimers and fibrinogen. This coagulopathy is associated with an increased risk of death. Furthermore, a substantial proportion of patients with severe COVID-19 develop sometimes unrecognized, venous, and arterial thromboembolic complications. A better understanding of COVID-19 pathophysiology, in particular hemostatic disorders, will help to choose appropriate treatment strategies. A rigorous thrombotic risk assessment and the implementation of a suitable anticoagulation strategy are required. We review here the characteristics of COVID-19 coagulation laboratory findings in affected patients, the incidence of thromboembolic events and their specificities, and potential therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.